This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
PsyBio is a biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders. The team has experience in drug discovery based on synthetic biology as well as clinical and regulatory experience moving drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of halucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company is also researching and developing new non-naturally occurring molecular structures which may have unique therapeutics properties.
Stock Performance
PsyBio Therapeutics News 17 articles
- PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
- PsyBio Announces Closing of First Tranche of Private Placement and Provides Corporate Update
- PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT
- PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio
- PsyBio Therapeutics Announces Non-Brokered Private Placement Financing
- PsyBio Therapeutics Reports Third Quarter 2022 Financial Results
- PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial
- Evan Levine, CEO of PsyBio Therapeutics, Sits in the Investor Hotseat on October 13th
- PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted
- PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022
- PsyBio Therapeutics Reports Second Quarter 2022 Financial Results
- PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application
- PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications
- PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with FDA
- PsyBio Therapeutics to List on OTCQX
- PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange
- PsyBio Therapeutics and Leo Acquisitions Announce Closing of CAD$14.5 Million Oversubscribed Private Placement